Brief: Everest Medicines Says Aggregate Consideration Under Share Purchase Agreement Is $250 Million
08/04/2026 01:05
April 8 (Reuters) - Everest Medicines 1952.HK: AGGREGATE CONSIDERATION UNDER SHARE PURCHASE AGREEMENT IS US$250 MILLION UNIT TO BUY ENTIRE EQUITY INTEREST IN HASTEN BIOPHARMACEUTICALS (SG) PTE Further company coverage: 1952.HK ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region